Compare NTB & INSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NTB | INSP |
|---|---|---|
| Founded | 1858 | 2007 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.2B |
| IPO Year | 2016 | 2018 |
| Metric | NTB | INSP |
|---|---|---|
| Price | $52.57 | $71.84 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 16 |
| Target Price | $50.67 | ★ $127.40 |
| AVG Volume (30 Days) | 156.9K | ★ 1.3M |
| Earning Date | 02-09-2026 | 02-11-2026 |
| Dividend Yield | ★ 3.79% | N/A |
| EPS Growth | 17.07 | ★ 34.77 |
| EPS | ★ 5.27 | 1.48 |
| Revenue | $599,452,000.00 | ★ $882,622,000.00 |
| Revenue This Year | $4.78 | $15.30 |
| Revenue Next Year | N/A | $10.84 |
| P/E Ratio | ★ $10.02 | $49.76 |
| Revenue Growth | 4.60 | ★ 16.81 |
| 52 Week Low | $34.86 | $70.77 |
| 52 Week High | $53.08 | $203.12 |
| Indicator | NTB | INSP |
|---|---|---|
| Relative Strength Index (RSI) | 64.87 | 27.75 |
| Support Level | $50.76 | $77.75 |
| Resistance Level | $51.89 | $84.24 |
| Average True Range (ATR) | 0.93 | 4.91 |
| MACD | 0.16 | -1.27 |
| Stochastic Oscillator | 70.47 | 2.00 |
Bank of N.T Butterfield & Son Ltd is a full-service bank and wealth manager. It operates the business through three geographic segments, Bermuda, Cayman Islands, the Channel Islands and the UK. The company offers banking services, comprised of retail and corporate banking, and wealth management, which consists of trust, private banking, and asset management. The company generates a majority of its revenue from Bermuda, and the Cayman Islands segments.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.